1. Home
  2. HBNC vs GERN Comparison

HBNC vs GERN Comparison

Compare HBNC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Horizon Bancorp Inc.

HBNC

Horizon Bancorp Inc.

HOLD

Current Price

$19.78

Market Cap

962.4M

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.36

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBNC
GERN
Founded
1873
1990
Country
United States
United States
Employees
N/A
258
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
962.4M
808.3M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
HBNC
GERN
Price
$19.78
$1.36
Analyst Decision
Buy
Hold
Analyst Count
4
3
Target Price
$21.00
$2.17
AVG Volume (30 Days)
833.8K
14.7M
Earning Date
04-22-2026
05-06-2026
Dividend Yield
3.57%
N/A
EPS Growth
N/A
N/A
EPS
0.51
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
$5.52
$43.75
P/E Ratio
$38.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.84
$1.04
52 Week High
$20.51
$2.01

Technical Indicators

Market Signals
Indicator
HBNC
GERN
Relative Strength Index (RSI) 56.30 58.68
Support Level $17.18 $1.23
Resistance Level $19.93 $1.46
Average True Range (ATR) 0.45 0.08
MACD 0.02 0.02
Stochastic Oscillator 59.83 68.57

Price Performance

Historical Comparison
HBNC
GERN

About HBNC Horizon Bancorp Inc.

Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: